Medtronic and Asan Medical Center sign MOU to establish strategic partnership in robotic surgery

• Establishes a comprehensive foundation for collaboration including clinical research, education, and technology development related to the Hugo robotic-surgery system
• Mike Marinaro, Executive Vice President and President, Medical Surgical Portfolio, Americas and Global Commercial Operations, Medtronic, visited Korea, emphasizing Korea's strategic importance in expanding the adoption of robotic surgery and reaffirming the commitment to partnership

Seoul, Korea - May 20, 2026 - Medtronic, a global leader in healthcare technology, and Asan Medical Center have signed a Memorandum of Understanding (MOU) to advance robotic surgery on May 6. The signing ceremony was attended by key representatives from both organizations, including Seung-il Park, President of Asan Medical Center (AMC); Dal-san Yoo, Director of the Robotic Surgery Center of AMC; Mike Marinaro, Executive Vice President and President of the Medical Surgical Portfolio, Medtronic; and Rok Yoo, Vice President, Medtronic Korea Ltd.

This MOU is designed to foster the advancement and broader adoption of robotic surgery and drive technology development utilizing Hugo™ RAS, Medtronic's robotic-assisted surgery system. Building on this agreement, the two organizations will collaborate closely across critical areas, including clinical research, education, and technology development, essential to the progression of robotic surgery.

Dalsan You, Director of the Robotic Surgery Center of AMC, stated, "Asan Medical Center has consistently contributed to the advancement of healthcare in Korea through its extensive clinical expertise and educational experience in complex and high-acuity care, including robotic surgery. Through this comprehensive collaboration with Medtronic, we aim to further advance the field of robotic surgery and reinforce our position as a leading global robotic surgery center."

Mike Marinaro, Executive Vice President and President of the Medical Surgical Portfolio, Medtronic, commented, "We are pleased to establish a partnership with Asan Medical Center which possesses world-class capabilities and experience in this field. Through this collaboration, we will strengthen our partnership with Korea, a strategic hub for the advancement of robotic surgery, and expand our support in the region."

Medtronic has been at the forefront of surgical tools and technological advancements in surgery for over 60 years, shaping the era of minimally invasive surgery. The company delivers solutions across all modalities of surgery, including open, laparoscopic, and robotic procedures. Hugo™ RAS is Medtronic's state-of-the-art robotic surgery system, integrating advanced surgical expertise. It features an open console for real-time team communication and a modular architecture allowing flexible positioning of robotic arms according to patient anatomy and procedural requirements.

Following earlier regulatory approval in Europe (2021), Japan (2023), and Korea (2024), the system received U.S. FDA clearance for urologic surgical procedures in December 2025. Its first surgeries in the United States commenced at major American medical institutions in February 2026. Outside the U.S., the Hugo RAS system has been used in tens of thousands of urologic, gynecologic, and general surgery procedures in more than 30 countries across 5 continents.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic.

Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

About Medtronic Korea

Medtronic Korea Ltd., the subsidiary of Medtronic, has been a part of Korea's journey toward advancing its healthcare landscape for nearly 40 years, beginning with the establishment of its liaison office in 1987 and its incorporation as a legal entity in 2000. With approximately 500 employees, the company delivers innovative medical technologies, products, and services to patients and healthcare professionals throughout Korea. In 2013, Medtronic Korea opened the Medtronic Innovation Center in the Osong Advanced Medical Complex, Korea's first research and surgical skills training center for medical devices. Since then, the company has continued to invest in the country's surgical research and educational infrastructure. The company has been recognized as a "Great Place to Work" by various evaluation organizations for fostering a work environment that promotes the mutual growth of the company, its employees, and the local community.

Contacts:

Hyunsu Lee

Communications

+82-2-3404-3161

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.